ORLANDO - LensAR, a developer of advanced 3D imaging technology for cataract surgery, announced the closing of a $24 million private financing which included investments from Aisling Capital and Florida Growth Fund. The financing will support first commercial shipments of the LensAR Laser System in the United States, Europe and select markets worldwide. Additionally, the financing will support ongoing research and development activities for the LensAR Laser System in additional clinical applications.
“The LensAR Laser System has been designed from the ground up around a single purpose - to give the cataract surgeon leading-edge laser technology while maintaining the usual workflows of a busy practice,” said Steve Elms, Managing Partner at Aisling Capital and Chairman of LensAR’s Board of Directors. “This financial commitment by Aisling and FGF reflects our excitement around a best-in-class system addressing a large market in its infancy.”
LensAR also announced the appointment of Nick Curtis, the company’s Chief Commercial Officer, as interim Chief Executive Officer. Previous CEO Randy Frey will remain a member of LensAR’s Board of Directors and also serve as a consultant to the Company.
Additionally, the Company announced that it is completing preparations for the installation of its second clinical system at the Instituto de Ojos Sacro Cuore in Lima, Peru. LensAR will be coordinating visits to this site for members of the Company’s medical advisory board, as well as for key opinion leaders from Topcon Medical Europe and for other select surgeons.
The Company’s first system was installed at the Asian Eye Institute in the Philippines.